<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT02257294</url>
  </required_header>
  <id_info>
    <org_study_id>GN12CA450</org_study_id>
    <secondary_id>12/170/45</secondary_id>
    <nct_id>NCT02257294</nct_id>
  </id_info>
  <brief_title>A Trial of Low-dose Adjunctive alTeplase During prIMary PCI</brief_title>
  <acronym>T-TIME</acronym>
  <official_title>A Randomised, Double Blind, Placebo-controlled, Parallel Group Trial of Low-dose Adjunctive alTeplase During prIMary PCI</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NHS Greater Glasgow and Clyde</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Glasgow</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute for Health Research, United Kingdom</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>NHS Greater Glasgow and Clyde</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety and efficacy of reduced doses (10 mg and&#xD;
      20 mg) of intra-coronary alteplase compared with placebo as an adjunct to PCI in reducing MVO&#xD;
      and its consequences in high risk patients with STEMI.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Despite numerous interventions, there remains a need to develop new ways to prevent&#xD;
      microvascular obstruction (MVO). The investigators aim to select patients with persistent&#xD;
      S-T-elevation on the ECG and an occluded artery and heavy thrombus burden at initial&#xD;
      angiography. These characteristics are causally linked to MVO. Patients with a thrombotic&#xD;
      culprit coronary artery have reduced myocardial perfusion compared to those without and the&#xD;
      presence of coronary thrombus is an independent predictor of adverse ischaemic outcomes&#xD;
      post-MI. Intra-luminal thrombus, as revealed by intra vascular imaging with optical coherence&#xD;
      tomography (OCT) in STEMI patients, has shown that thrombus commonly persists in the culprit&#xD;
      coronary artery, including within the stent post-implantation, even when the thrombus is&#xD;
      invisible with conventional angiography. The amount of persistent thrombus predicted the&#xD;
      likelihood of persistent S-T-segment elevation, a marker of microvascular injury, and&#xD;
      impaired perfusion.Therefore, coronary thrombus represents a therapeutic target in primary&#xD;
      PCI. The pathophysiology of MVO and microvascular thrombosis has elucidated in MRI studies of&#xD;
      reperfused MI in swine. The investigators demonstrated that LATE MVO corresponds closely with&#xD;
      infarct zone haemorrhage as revealed by T2-weighted MRI and pathology. The investigators&#xD;
      observations were validated by Robbers et al who showed that in swine 7 days post-MI, when&#xD;
      LATE MVO and haemorrhage correspond (which is usually the case), there is severe capillary&#xD;
      loss and disruption coupled with thrombosis and inflammation. They concluded that following&#xD;
      reperfusion, acute inflammation and microvessel thrombosis result in degradation of&#xD;
      endothelial integrity and capillary breakdown. Very interestingly, their histology also&#xD;
      demonstrated diffuse microvascular thrombosis within the area of late gadolinium enhancement&#xD;
      surrounding the haemorrhagic core which explains reduced perfusion (or wash during first pass&#xD;
      of gadolinium contrast MRI) within the ischaemic area-at-risk. This observation points to the&#xD;
      therapeutic potential of local thrombolysis within the culprit artery circulation.The study&#xD;
      addresses the question of whether a pharmacological strategy involving reduced dose alteplase&#xD;
      given early during the primary PCI procedure will both prevent and treat distal microvascular&#xD;
      thrombosis and MVO and, subsequently, reduce infarct size.Current evidence around the&#xD;
      potential safety and efficacy of reduced dose fibrinolysis in primary PCI is limited. These&#xD;
      limitations set-the-scene and support the rationale for the clinical trial: Full systemic&#xD;
      dose intravenous fibrinolysis to facilitate primary PCI is potentially harmful and increases&#xD;
      the risk of off-target bleeding complications; therefore, the investigators will use&#xD;
      reduced-dose fibrinolysis. They will directly infuse alteplase into the culprit artery to&#xD;
      achieve effective and sustained local plasma concentrations and much lower systemic&#xD;
      concentrations of unbound drug. It is anticipated that bleeding rates may be low; therefore,&#xD;
      the investigators will measure fibrinogen in all patients. Fibrinogen and other haemostasis&#xD;
      parameters will serve as a surrogate measure of bleeding (and safety). In line with&#xD;
      contemporary practice, investigators advise that patients have radial artery access whenever&#xD;
      possible. Previous trials have used streptokinase (non-fibrin specific and immunogenic); this&#xD;
      study will use the fibrin-specific non-immunogenic second generation thrombolytic, alteplase&#xD;
      The only previous trial involved thrombolysis at the end of primary PCI (when microvascular&#xD;
      thrombosis may already be established after reperfusion); the efficacy of thrombolysis may be&#xD;
      greatest when thrombus is most abundant at the beginning of primary PCI; persistent residual&#xD;
      fibrin strands adherent within the culprit territory will be selectively targeted by&#xD;
      fibrinolytic therapy during primary PCI; thrombus which forms during the primary PCI&#xD;
      procedure could be treated by the sustained 'deep tissue' thrombolytic effects of locally&#xD;
      administered intra-coronary alteplase; in terms of ease-of-use and feasibility, there may be&#xD;
      advantages to giving alteplase as a single dose.T-TIME is a Phase II evaluation of two&#xD;
      reduced doses of alteplase, delivered locally, compared to placebo in STEMI patients&#xD;
      receiving PCI in a double-blind, randomised, parallel group, placebo-controlled dose-ranging&#xD;
      clinical trial. The investigators believe the strategy with intracoronary fibrinolysis&#xD;
      complements other therapeutic approaches which are currently being tested. Should the trial&#xD;
      demonstrate EFFICACY then a future trial might involve a factorial design with placebo,&#xD;
      alteplase and any other intervention that might also be shown to be effective in the&#xD;
      intervening time in order to test the comparative EFFICACY of each (alone or in combination)&#xD;
      on surrogate and/or clinical outcomes.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 2016</start_date>
  <completion_date type="Actual">May 8, 2019</completion_date>
  <primary_completion_date type="Actual">July 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The amount of MVO (% of Left Ventricular (LV) mass) revealed by late (10 - 15 min) gadolinium contrast enhancement MRI 2 days post-MI.</measure>
    <time_frame>2-7 days</time_frame>
    <description>Amount of MVO (% of LV mass) revealed by late gadolinium contrast-enhanced MRI 10-15 minutes after contrast administration on an MRI scan performed 2-7 days post-MI.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Angiogram</measure>
    <time_frame>0-2 hours</time_frame>
    <description>TIMI Coronary flow grade at the end of PCI; TIMI blush grade at the end of PCI; TIMI frame count at the end of PCI; TIMI thrombus grade at the end of PCI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ECG</measure>
    <time_frame>0-2 hours</time_frame>
    <description>% ST segment resolution on the 12-lead ECG (pre- vs. 60 mins post-reperfusion with primary PCI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Haematology</measure>
    <time_frame>24 hours</time_frame>
    <description>Coagulation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MRI</measure>
    <time_frame>2-7 days</time_frame>
    <description>Late MVO (presence/absence); Infarct size; Myocardial salvage index (infarct size/area-at-risk); LV end-diastolic volume (LVEDV); LV end-systolic volume (LVESV); LV ejection fraction (LVEF); Myocardial haemorrhage (presence/absence); Myocardial haemorrhage extent (% of LV)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety</measure>
    <time_frame>2-7 days</time_frame>
    <description>Acute cerebral (stroke) and systemic (GI, peripheral) bleeding (if any) with alteplase; Coagulation (fibrinogen concentration);</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MRI</measure>
    <time_frame>12 weeks</time_frame>
    <description>Infarct size; Myocardial salvage index (final infarct size/initial area-at-risk); LV end-diastolic volume (LVEDV); LV end-systolic volume (LVESV); LV ejection fraction (LVEF);</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ECG</measure>
    <time_frame>12 weeks</time_frame>
    <description>ECG for final infarct size</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biochemistry</measure>
    <time_frame>12 weeks</time_frame>
    <description>Troponin T; NT-pro BNP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>12 weeks</time_frame>
    <description>EQ5D-5L assessment (2-7 days, 12 weeks)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Histopathology (sub-study)</measure>
    <time_frame>0 hours</time_frame>
    <description>Fibrin histopathology in thrombus aspirate</description>
  </other_outcome>
  <other_outcome>
    <measure>Angiogram</measure>
    <time_frame>0-2 hours</time_frame>
    <description>Intra-procedural changes in TIMI Coronary Flow Grade; Intra-procedural changes in TIMI blush grade; Intra-procedural changes in TIMI Frame Count; Intra-procedural changes in TIMI Thrombus Grade; Intra-procedural thrombotic events</description>
  </other_outcome>
  <other_outcome>
    <measure>Coronary Physiology (sub-study)</measure>
    <time_frame>0-2 hours</time_frame>
    <description>IMR; CFR</description>
  </other_outcome>
  <other_outcome>
    <measure>Optical Coherence Tomography (sub-study)</measure>
    <time_frame>0-2 hours</time_frame>
    <description>Thrombus area</description>
  </other_outcome>
  <other_outcome>
    <measure>Biochemistry</measure>
    <time_frame>24 hours</time_frame>
    <description>Blood chemistry (standard of care blood tests)</description>
  </other_outcome>
  <other_outcome>
    <measure>Haematology</measure>
    <time_frame>24 hour</time_frame>
    <description>Haemoglobin (standard of care blood tests)</description>
  </other_outcome>
  <other_outcome>
    <measure>Safety</measure>
    <time_frame>24 hours</time_frame>
    <description>Haemoglobin (standard of care blood tests)</description>
  </other_outcome>
  <other_outcome>
    <measure>ECG</measure>
    <time_frame>12 weeks</time_frame>
    <description>Surrogate ECG measures of infarct size - Anderson ST Acuteness score and Selvester QRS score; Acuteness of the ECG changes - Anderson Wilkins score;</description>
  </other_outcome>
  <other_outcome>
    <measure>MRI</measure>
    <time_frame>12 weeks</time_frame>
    <description>First pass MVO extent (% of LV); Early MVO extent (% of LV) on 1 min post-gadolinium contrast enhanced MRI , adjusted for area-at-risk at baseline; LV remodelling index (minimum infarct wall thickness / maximum remote zone thickness mid-diastole); LV diastolic myocardial wall thickness to volume; LV sphericity index at end diastole (maximal longitudinal LV diameter (i.e. tip mitral valve to LV index) / maximal short-axis diameter); LV sphericity index at end-systole (maximal longitudinal LV diameter (i.e. tip mitral valve to LV apex) / maximal short-axis diameter); LV wall motion; Myocardial strain; Myocardial haemorrhage; Myocardial perfusion in the infarct zone; Myocardial perfusion in the remote zone; Infarct zone perfusion indexed to remote zone perfusion; Extracellular volume in the infarct zone; Extracellular volume in the remote zone; Extracellular in the infarct core; LV wall motion;</description>
  </other_outcome>
  <other_outcome>
    <measure>Quality of life</measure>
    <time_frame>2 years</time_frame>
    <description>Blood chemistry (standard of care blood tests); EQ5D-5L (52 weeks)</description>
  </other_outcome>
  <other_outcome>
    <measure>Health outcomes</measure>
    <time_frame>3 years</time_frame>
    <description>Death; MI; Heart Failure; Stroke/TIA; Acute bleeds</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">440</enrollment>
  <condition>Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>Control Arm</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>two placebo vials</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Alteplase 10mg and placebo vial</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Alteplase 10mg and alteplase 10mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alteplase</intervention_name>
    <description>Single treatment consisting of a single slow infusion administration after reperfusion with aspiration thrombectomy ± angioplasty but before stenting during primary PCI.</description>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
    <other_name>Actilyse</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Single treatment consisting of a single slow infusion administration after reperfusion with aspiration thrombectomy ± angioplasty but before stenting during primary PCI.</description>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Control Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Males aged ≥ 18 years; females ≤ 18 years not of child bearing potential (defined as&#xD;
             women who are post-menopausal or permanently sterilised (e.g. hysterectomy, tubal&#xD;
             occlusion, bilateral salpingectomy)&#xD;
&#xD;
          -  Acute myocardial infarction (symptoms onset ≤ 6 hours) with persistent ST-segment&#xD;
             elevation or recent left bundle branch block&#xD;
&#xD;
          -  Coronary artery occlusion (TIMI coronary flow grade 0 or 1) OR Impaired coronary flow&#xD;
             (TIMI flow grade 2, slow but complete filling) in the presence of definite&#xD;
             angiographic evidence of thrombus (TIMI grade 2+)&#xD;
&#xD;
          -  Proximal-mid culprit lesion location in a major coronary artery (ie the right, left&#xD;
             anterior descending, intermediate or circumflex coronary artery)&#xD;
&#xD;
          -  Radial artery access&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Shock (systolic blood pressure &lt;90 mmHg with clinical signs of peripheral&#xD;
             hypoperfusion despite adequate filling)&#xD;
&#xD;
          -  Normal coronary flow grade (TIMI flow grade 3) at initial angiography&#xD;
&#xD;
          -  Functional coronary collateral supply (Rentrop grade 2/3) to culprit artery&#xD;
&#xD;
          -  Multivessel PCI intended before the day 2-7 MRI Scan&#xD;
&#xD;
          -  Non-cardiac co-morbidity with expected survival &lt;1 year&#xD;
&#xD;
          -  Estimated body weight &lt;60kg&#xD;
&#xD;
          -  Contra-indication to contrast-enhanced MRI&#xD;
&#xD;
          -  Pacemaker&#xD;
&#xD;
          -  Implantable defibrillator&#xD;
&#xD;
          -  estimated Glomerular Filtration Rate (eGFR) &lt;30ml/min/1.73m²&#xD;
&#xD;
          -  previous infarction in the culprit artery (known or suspected clinically, e.g. wall&#xD;
             motion abnormality revealed by echocardiography)&#xD;
&#xD;
          -  Significant bleeding problem either at present or within the past 6 months&#xD;
&#xD;
          -  Patients with current concomitant oral anticoagulant therapy (INR &gt; 1.3), including&#xD;
             apixaban, dabigatran and rivaroxaban&#xD;
&#xD;
          -  Any history of central nervous system damage (i.e. neoplasm, aneurysm, intracranial,&#xD;
             or spinal surgery)&#xD;
&#xD;
          -  Known Haemorrhagic diathesis&#xD;
&#xD;
          -  Severe uncontrolled hypertension &gt;180/110 mmHg not controlled by medical therapy&#xD;
&#xD;
          -  Major surgery, biopsy of a parenchymal organ, or significant trauma within the past 2&#xD;
             months (this includes any trauma associated with the current STEMI)&#xD;
&#xD;
          -  Recent trauma to the head or cranium (&lt;2 months)&#xD;
&#xD;
          -  Prolonged cardiopulmonary resuscitation (&gt;2 minutes) within past 2 weeks&#xD;
&#xD;
          -  Acute pericarditis and/or subacute bacterial endocarditis e.g. valve mass or&#xD;
             vegetation revealed by echocardiography&#xD;
&#xD;
          -  Acute pancreatitis&#xD;
&#xD;
          -  Severe hepatic dysfunction, including hepatic failure, cirrhosis, portal hypertension&#xD;
             (oesophageal varices) and active hepatitis&#xD;
&#xD;
          -  Arterial aneurysm and known arterial/venous malformation&#xD;
&#xD;
          -  Neoplasm with increased bleeding risk&#xD;
&#xD;
          -  Any known history of haemorrhagic stroke or stroke of unknown origin&#xD;
&#xD;
          -  Known history of ischaemic stroke or transient ischaemic attack &lt;6 months&#xD;
&#xD;
          -  Dementia&#xD;
&#xD;
          -  Hypersensitivity to gentamicin&#xD;
&#xD;
          -  Women of child-bearing potential (i.e. pre-menopause) or breast feeding&#xD;
&#xD;
          -  Previous randomisation to this study or participation in a study with an&#xD;
             investigational drug or medical device within 90 days prior to randomisation&#xD;
&#xD;
          -  Incapacity or inability to provide informed consent&#xD;
&#xD;
          -  requirement for immunosuppressive drug therapy at any time during the past 3 months;&#xD;
             whether administered orally, subcutaneously or intravenously. This would include&#xD;
             corticosteroids (but not inhaled or topical), drugs used following transplantation&#xD;
             (e.g. tacrolimus, cyclosporine), anti-metabolite therapies (e.g. mycophenolic acid&#xD;
             (Myfortic), azathioprine, leflunomide (Arava)), and immunomodulators including&#xD;
             biologics (e.g. adalimumab (HUMIRA), etanercept (Enbrel), aldesleukin), and DMARDS&#xD;
             (cyclophosphamide. methotrexate, etc). Please note that this list is not exhaustive&#xD;
             and a requirement for other immunosuppressive drugs not listed would also exclude the&#xD;
             patient.&#xD;
&#xD;
          -  active or prophylactic treatment with oral or parenteral antibiotic, antifungal or&#xD;
             antiviral therapy to prevent or treat infection.&#xD;
&#xD;
          -  any anti-cancer treatment (excluding surgery as this is covered above) at any time&#xD;
             during the past 3 months including chemotherapy, radiotherapy and treatment with&#xD;
             biologics such as Vascular Endothelial Growth Factor Receptor (VEGFR) inhibitors (e.g.&#xD;
             bevacizumab, pazopanib). This list is not exhaustive and the sponsor or CI should be&#xD;
             contacted for advice if required.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Colin Berry, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Glasgow</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Edinburgh Royal Infirmary</name>
      <address>
        <city>Edinburgh</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Golden Jubilee National Hospital</name>
      <address>
        <city>Glasgow</city>
        <zip>G81 4HX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leeds General Infirmary</name>
      <address>
        <city>Leeds</city>
        <zip>LS1 3EX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Glenfield Hospital</name>
      <address>
        <city>Leicester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Liverpool Heart and Chest Hospital</name>
      <address>
        <city>Liverpool</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Barts Health Centre, St Bartholomew's Hospital</name>
      <address>
        <city>London</city>
        <zip>EC1A 7BE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital of South Manchester NHS Foundation Trust</name>
      <address>
        <city>Manchester</city>
        <zip>M23 9LT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>James Cook University Hospital</name>
      <address>
        <city>Middlesbrough</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Freeman Hospital</name>
      <address>
        <city>Newcastle</city>
        <zip>NE7 7DN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Southampton NHS Foundation Trust</name>
      <address>
        <city>Southampton</city>
        <zip>SO16 6TD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Heart and Lung Centre, New Cross Hospital</name>
      <address>
        <city>Wolverhampton</city>
        <zip>WV10 0QP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>September 26, 2014</study_first_submitted>
  <study_first_submitted_qc>October 3, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 6, 2014</study_first_posted>
  <last_update_submitted>September 4, 2019</last_update_submitted>
  <last_update_submitted_qc>September 4, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 6, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tissue Plasminogen Activator</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT02257294
org study id: GN12CA450
secondary id: 12/170/45
nct id: NCT02257294
lead sponsor: 
collaborator: 
collaborator: 
has dmc: Yes
The purpose of this study is to determine the safety and efficacy of reduced doses (10 mg and
      20 mg) of intra-coronary alteplase compared with placebo as an adjunct to PCI in reducing MVO
      and its consequences in high risk patients with STEMI.
Despite numerous interventions, there remains a need to develop new ways to prevent
      microvascular obstruction (MVO). The investigators aim to select patients with persistent
      S-T-elevation on the ECG and an occluded artery and heavy thrombus burden at initial
      angiography. These characteristics are causally linked to MVO. Patients with a thrombotic
      culprit coronary artery have reduced myocardial perfusion compared to those without and the
      presence of coronary thrombus is an independent predictor of adverse ischaemic outcomes
      post-MI. Intra-luminal thrombus, as revealed by intra vascular imaging with optical coherence
      tomography (OCT) in STEMI patients, has shown that thrombus commonly persists in the culprit
      coronary artery, including within the stent post-implantation, even when the thrombus is
      invisible with conventional angiography. The amount of persistent thrombus predicted the
      likelihood of persistent S-T-segment elevation, a marker of microvascular injury, and
      impaired perfusion.Therefore, coronary thrombus represents a therapeutic target in primary
      PCI. The pathophysiology of MVO and microvascular thrombosis has elucidated in MRI studies of
      reperfused MI in swine. The investigators demonstrated that LATE MVO corresponds closely with
      infarct zone haemorrhage as revealed by T2-weighted MRI and pathology. The investigators
      observations were validated by Robbers et al who showed that in swine 7 days post-MI, when
      LATE MVO and haemorrhage correspond (which is usually the case), there is severe capillary
      loss and disruption coupled with thrombosis and inflammation. They concluded that following
      reperfusion, acute inflammation and microvessel thrombosis result in degradation of
      endothelial integrity and capillary breakdown. Very interestingly, their histology also
      demonstrated diffuse microvascular thrombosis within the area of late gadolinium enhancement
      surrounding the haemorrhagic core which explains reduced perfusion (or wash during first pass
      of gadolinium contrast MRI) within the ischaemic area-at-risk. This observation points to the
      therapeutic potential of local thrombolysis within the culprit artery circulation.The study
      addresses the question of whether a pharmacological strategy involving reduced dose alteplase
      given early during the primary PCI procedure will both prevent and treat distal microvascular
      thrombosis and MVO and, subsequently, reduce infarct size.Current evidence around the
      potential safety and efficacy of reduced dose fibrinolysis in primary PCI is limited. These
      limitations set-the-scene and support the rationale for the clinical trial: Full systemic
      dose intravenous fibrinolysis to facilitate primary PCI is potentially harmful and increases
      the risk of off-target bleeding complications; therefore, the investigators will use
      reduced-dose fibrinolysis. They will directly infuse alteplase into the culprit artery to
      achieve effective and sustained local plasma concentrations and much lower systemic
      concentrations of unbound drug. It is anticipated that bleeding rates may be low; therefore,
      the investigators will measure fibrinogen in all patients. Fibrinogen and other haemostasis
      parameters will serve as a surrogate measure of bleeding (and safety). In line with
      contemporary practice, investigators advise that patients have radial artery access whenever
      possible. Previous trials have used streptokinase (non-fibrin specific and immunogenic); this
      study will use the fibrin-specific non-immunogenic second generation thrombolytic, alteplase
      The only previous trial involved thrombolysis at the end of primary PCI (when microvascular
      thrombosis may already be established after reperfusion); the efficacy of thrombolysis may be
      greatest when thrombus is most abundant at the beginning of primary PCI; persistent residual
      fibrin strands adherent within the culprit territory will be selectively targeted by
      fibrinolytic therapy during primary PCI; thrombus which forms during the primary PCI
      procedure could be treated by the sustained 'deep tissue' thrombolytic effects of locally
      administered intra-coronary alteplase; in terms of ease-of-use and feasibility, there may be
      advantages to giving alteplase as a single dose.T-TIME is a Phase II evaluation of two
      reduced doses of alteplase, delivered locally, compared to placebo in STEMI patients
      receiving PCI in a double-blind, randomised, parallel group, placebo-controlled dose-ranging
      clinical trial. The investigators believe the strategy with intracoronary fibrinolysis
      complements other therapeutic approaches which are currently being tested. Should the trial
      demonstrate EFFICACY then a future trial might involve a factorial design with placebo,
      alteplase and any other intervention that might also be shown to be effective in the
      intervening time in order to test the comparative EFFICACY of each (alone or in combination)
      on surrogate and/or clinical outcomes.
allocation: Randomized
intervention model: Parallel Assignment
primary purpose: Treatment
masking: Triple (Participant, Care Provider, Investigator)
measure: The amount of MVO (% of Left Ventricular (LV) mass) revealed by late (10 - 15 min) gadolinium contrast enhancement MRI 2 days post-MI.
time frame: 2-7 days
description: Amount of MVO (% of LV mass) revealed by late gadolinium contrast-enhanced MRI 10-15 minutes after contrast administration on an MRI scan performed 2-7 days post-MI.
measure: Angiogram
time frame: 0-2 hours
description: TIMI Coronary flow grade at the end of PCI; TIMI blush grade at the end of PCI; TIMI frame count at the end of PCI; TIMI thrombus grade at the end of PCI
measure: ECG
time frame: 0-2 hours
description: % ST segment resolution on the 12-lead ECG (pre- vs. 60 mins post-reperfusion with primary PCI)
measure: Haematology
time frame: 24 hours
description: Coagulation
measure: MRI
time frame: 2-7 days
description: Late MVO (presence/absence); Infarct size; Myocardial salvage index (infarct size/area-at-risk); LV end-diastolic volume (LVEDV); LV end-systolic volume (LVESV); LV ejection fraction (LVEF); Myocardial haemorrhage (presence/absence); Myocardial haemorrhage extent (% of LV)
measure: Safety
time frame: 2-7 days
description: Acute cerebral (stroke) and systemic (GI, peripheral) bleeding (if any) with alteplase; Coagulation (fibrinogen concentration);
measure: MRI
time frame: 12 weeks
description: Infarct size; Myocardial salvage index (final infarct size/initial area-at-risk); LV end-diastolic volume (LVEDV); LV end-systolic volume (LVESV); LV ejection fraction (LVEF);
measure: ECG
time frame: 12 weeks
description: ECG for final infarct size
measure: Biochemistry
time frame: 12 weeks
description: Troponin T; NT-pro BNP
measure: Quality of Life
time frame: 12 weeks
description: EQ5D-5L assessment (2-7 days, 12 weeks)
measure: Histopathology (sub-study)
time frame: 0 hours
description: Fibrin histopathology in thrombus aspirate
measure: Angiogram
time frame: 0-2 hours
description: Intra-procedural changes in TIMI Coronary Flow Grade; Intra-procedural changes in TIMI blush grade; Intra-procedural changes in TIMI Frame Count; Intra-procedural changes in TIMI Thrombus Grade; Intra-procedural thrombotic events
measure: Coronary Physiology (sub-study)
time frame: 0-2 hours
description: IMR; CFR
measure: Optical Coherence Tomography (sub-study)
time frame: 0-2 hours
description: Thrombus area
measure: Biochemistry
time frame: 24 hours
description: Blood chemistry (standard of care blood tests)
measure: Haematology
time frame: 24 hour
description: Haemoglobin (standard of care blood tests)
measure: Safety
time frame: 24 hours
description: Haemoglobin (standard of care blood tests)
measure: ECG
time frame: 12 weeks
description: Surrogate ECG measures of infarct size - Anderson ST Acuteness score and Selvester QRS score; Acuteness of the ECG changes - Anderson Wilkins score;
measure: MRI
time frame: 12 weeks
description: First pass MVO extent (% of LV); Early MVO extent (% of LV) on 1 min post-gadolinium contrast enhanced MRI , adjusted for area-at-risk at baseline; LV remodelling index (minimum infarct wall thickness / maximum remote zone thickness mid-diastole); LV diastolic myocardial wall thickness to volume; LV sphericity index at end diastole (maximal longitudinal LV diameter (i.e. tip mitral valve to LV index) / maximal short-axis diameter); LV sphericity index at end-systole (maximal longitudinal LV diameter (i.e. tip mitral valve to LV apex) / maximal short-axis diameter); LV wall motion; Myocardial strain; Myocardial haemorrhage; Myocardial perfusion in the infarct zone; Myocardial perfusion in the remote zone; Infarct zone perfusion indexed to remote zone perfusion; Extracellular volume in the infarct zone; Extracellular volume in the remote zone; Extracellular in the infarct core; LV wall motion;
measure: Quality of life
time frame: 2 years
description: Blood chemistry (standard of care blood tests); EQ5D-5L (52 weeks)
measure: Health outcomes
time frame: 3 years
description: Death; MI; Heart Failure; Stroke/TIA; Acute bleeds
arm group label: Control Arm
arm group type: Placebo Comparator
description: two placebo vials
arm group label: Arm A
arm group type: Active Comparator
description: Alteplase 10mg and placebo vial
arm group label: Arm B
arm group type: Active Comparator
description: Alteplase 10mg and alteplase 10mg
intervention type: Drug
intervention name: Alteplase
description: Single treatment consisting of a single slow infusion administration after reperfusion with aspiration thrombectomy ± angioplasty but before stenting during primary PCI.
arm group label: Arm A
arm group label: Arm B
other name: Actilyse
intervention type: Other
intervention name: Placebo
description: Single treatment consisting of a single slow infusion administration after reperfusion with aspiration thrombectomy ± angioplasty but before stenting during primary PCI.
arm group label: Arm A
arm group label: Control Arm
criteria: 
gender: All
minimum age: 18 Years
maximum age: N/A
healthy volunteers: No
last name: Colin Berry, Prof
role: Principal Investigator
affiliation: University of Glasgow
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
country: United Kingdom
responsible party type: Sponsor
mesh term: Myocardial Infarction
mesh term: Infarction
mesh term: Tissue Plasminogen Activator